Specify a stock or a cryptocurrency in the search bar to get a summary
Ascletis Pharma Inc
2VJAscletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China. Address: Building D, Hangzhou, China, 311200
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 2VJ
Dividend Analytics 2VJ
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 2VJ
Stock Valuation 2VJ
Financials 2VJ
Results | 2019 | Dynamics |